Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.64 |
| ▸ | PDE4A | P27815 | 8/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256416 | 0.95 | KDM4E (0.66) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256417 | 0.95 | KDM4E (0.71) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256423 | 0.89 | PDE4B (0.79) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL5012438 | 0.85 | PDE4B (0.79) | KDM4EALDH1A1ADRB2HPGDPDE4B | |
| SCHEMBL24256385 | 0.85 | KDM4E (0.75) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256377 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256614 | 0.80 | HTT (0.55) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256613 | 0.79 | RAD52 (0.47) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL24256352 | 0.78 | POLB (0.51) | KDM4EALDH1A1LMNAADRB2GAA | |
| SCHEMBL5012378 | 0.78 | PDE4B (0.93) | KDM4EALDH1A1LMNAADRB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022035806-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | KDM4E 1927/4885ALDH1A1 1934/4885LMNA 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.